References
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
- Medeiros BC, Minden MD, Schuh AC, et al. Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leuk Lymphoma. 2007;48(1):65–67.
- Verma D, Kantarjian H, Faderl S, et al. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma. 2010;51(5):778–782.
- Watts JM, Wang XV, Litzow MR, et al. Younger adults with acute myeloid leukemia in remission for ≥3 years have a high likelihood of cure: the ECOG experience in over 1200 patients. Leuk Res. 2014;38(8):901–906.
- Yilmaz M, Wang F, Loghavi S, et al. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019;9(2):7.
- Bertoli S, Tavitian S, Huynh A, et al. Improved outcome for AML patients over the years 2000–2014. Blood Cancer J. 2017;7(12):635.
- Juliusson G, Lazarevic V, Hörstedt AS, et al. Swedish acute leukemia registry group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–3899.
- Østgård LS, Nørgaard JM, Raaschou-Jensen KK, et al. The danish national acute leukemia registry. Clin Epidemiol. 2016;8:553–560.
- Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc + AML): biologic and clinical features. Blood. 2007;109(3):874–885.
- Bolli N, Galimberti S, Martelli MP, et al. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol. 2006;7(4):350–352.
- Meloni G, Mancini M, Gianfelici V, et al. Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. Haematologica. 2009;94(2):298–300.
- Falini B, Martelli MP, Mecucci C, et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc + acute myeloid leukemia in SCID mice. Haematologica. 2008;93(5):775–779.
- Krönke J, Bullinger L, Teleanu V, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122(1):100–108.
- Höllein A, Meggendorfer M, Dicker F, et al. NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. Blood Adv. 2018;2(22):3118–3125.